Ago2 Antibody, Brachyury Antibody, Brn3A Antibody, Cd45Ro Antibody, Cdk5 Antibody, Erg Antibody, Foxa2 Antibody, Galr1 Antibody, Gerbil, Guinea, Hamster, Helicobacter, Human, Influenza, Insect, Kangaroo, Killifish, Klf2 Antibody, Lkb1 Antibody, Mobp Antibody, Parp1 Antibody, Pig, Raccoon, Rat, Reindeer, Reptile, Tbp Antibody, Zeb2 Antibody

Rapid purification and direct microassay of calbindin9kDa utilizing its solubility in perchloric acid.

by Frank Green
The 9 kDa calcium-binding protein, calbindin9kDa, was discovered to be soluble in 7% (v/v) perchloric acid. Calbindin9kDa was simply purified from rat duodenum in 1 day with perchloric acid precipitation adopted by reverse-phase h.p.l.c. The yield was 21.4 +/- 2.Three nmol/g moist weight of tissue (imply +/- S.E.M.; n = 3) from usually fed 7-8-week-old rats (approx. 70% restoration).
The purification was additionally efficient with rabbit duodenum calbindin9kDa, however not with numerous different EF-hand calcium-binding proteins examined within the rat. A number of standards (h.p.l.c., u.v. spectrum, denaturing two-dimensional PAGE, N-terminal sequencing) indicated that the rat calbindin9kDa was purified to homogeneity and was not affected by proteolysis.
Excessive-affinity calcium-binding properties have been retained and no proof of isoforms or cost modification was noticed. Residue 59, recognized as Asn (not Asp as beforehand reported), was totally amidated. When adopted as a microassay with isocratic h.p.l.c., the perchloric acid process enabled speedy (lower than 6 min) and direct (peptide bond absorbance) quantification of lower than 1 pmol of calbindin9kDa. This new strategy to purification and assay can be of specific utility for investigations of calbindin9kDa in beforehand intractable low-abundance sources (e.g. cultured cells).

Detection of GPCR mRNA Expression in Major Cells Through qPCR, Microarrays, and RNA-Sequencing

 

A workflow is described for assaying the expression of G protein-coupled receptors (GPCRs) in cultured cells, utilizing a mix of strategies that assess GPCR mRNAs. Starting from the isolation of cDNA and preparation of mRNA, we offer protocols for designing and testing qPCR primers, assaying mRNA expression utilizing qPCR and high-throughput evaluation of GPCR mRNA expression by way of TaqMan qPCR-based, GPCR-selective arrays.

We additionally present a workflow for evaluation of expression from RNA-sequencing (RNA-seq) assays, which could be queried to yield expression of GPCRs and associated genes in samples of curiosity, in addition to to check adjustments in expression between teams, reminiscent of in cells handled with medication or from wholesome and diseased topics.

We place precedence on optimized protocols that distinguish sign from noise, as GPCR mRNAs are sometimes current in low abundance, necessitating methods that maximize sensitivity whereas minimizing noise. These strategies might also be relevant for assessing the expression of members of households of different low abundance genes by way of high-throughput analyses of mRNAs, adopted by unbiased affirmation and validation of outcomes by way of qPCR.

Responsive Hydrogel Binding Matrix for Twin Sign Amplification in Fluorescence Affinity Biosensors and Peptide Microarrays

 

A mixed strategy to sign enhancement in fluorescence affinity biosensors and assays is reported. It’s based mostly on the compaction of particularly captured goal molecules on the sensor floor adopted by optical probing with a tightly confined floor plasmon (SP) subject. This idea is utilized through the use of a thermoresponsive hydrogel (HG) binding matrix that’s ready from a terpolymer derived from poly(N-isopropylacrylamide) (pNIPAAm) and hooked up to a metallic sensor floor. Epi-illumination fluorescence and SP-enhanced whole inner reflection fluorescence readouts of affinity binding occasions are carried out to spatially interrogate the fluorescent sign within the course parallel and perpendicular to the sensor floor.

The pNIPAAm-based HG binding matrix is organized in arrays of sensing spots and employed for the particular detection of human IgG antibodies in opposition to the Epstein-Barr virus (EBV). The detection is carried out in diluted human plasma or with remoted human IgG through the use of a set of peptide ligands mapping the epitope of the EBV nuclear antigen. Alkyne-terminated peptides have been covalently coupled to the pNIPAAm-based HG carrying azide moieties. Importantly, utilizing such low-molecular-weight ligands allowed preserving the thermoresponsive properties of the pNIPAAm-based structure, which was not doable for amine coupling of normal antibodies which have the next molecular weight.

Microarray evaluation reveals an inflammatory transcriptomic signature in peripheral blood for sciatica

 

Background: Though the pathology of sciatica has been studied extensively, the transcriptional adjustments within the peripheral blood brought on by sciatica haven’t been characterised. This examine aimed to characterize the peripheral blood transcriptomic signature for sciatica.

Strategies: We used a microarray to determine differentially expressed genes within the peripheral blood of sufferers with sciatica in contrast with that of wholesome controls, carried out a useful evaluation to disclose the peripheral blood transcriptomic signature for sciatica, and performed a community evaluation to determine key genes that contribute to the noticed transcriptional adjustments. The expression ranges of those key genes have been assessed by qRT-PCR.

Outcomes: We discovered that 153 genes have been differentially expressed within the peripheral blood of sufferers with sciatica in contrast with that of wholesome controls, and 131 and 22 of those have been upregulated and downregulated, respectively. A useful evaluation revealed that these differentially expressed genes (DEGs) have been strongly enriched for the inflammatory response or immunity. The community evaluation revealed {that a} group of genes, most of that are associated to the inflammatory response, performed a key function within the dysregulation of those DEGs. These key genes are Toll-like receptor 4, matrix metallopeptidase 9, myeloperoxidase, cathelicidin antimicrobial peptide, resistin and Toll-like receptor 5, and a qRT-PCR evaluation validated the upper transcript ranges of those key genes within the peripheral blood of sufferers with sciatica than in that of wholesome controls.

Conclusion: We revealed inflammatory traits that function a peripheral blood transcriptomic signature for sciatica and recognized genes which can be important for mRNA dysregulation within the peripheral blood of sufferers with sciatica.

Metabolic utilization of human osteoblast cell line hFOB 1.19 beneath normoxic and hypoxic situations: A phenotypic microarray evaluation

At the moment, researchers perceive that bone cells expertise hypoxia throughout bone harm or fracture. Such stress situation exerts impact on bone regeneration and restore. Nonetheless, there’s restricted data on the metabolites and metabolism adjustments that happen in osteoblast cells after they bear inherent regeneration and restore beneath hypoxia. This manuscript describes the usage of Phenotype MicroArrays to watch the response of human osteoblast cells beneath normoxic and hypoxic situations when it comes to cell development and utilization of metabolites.

The human osteoblast cultured beneath these two completely different oxygen concentrations confirmed completely different development curve and utilization of metabolites, suggesting oxygen ranges play a task in bone restore and therapeutic. We’ve got deduced the principle metabolites for osteoblast cells to provide vitality beneath normoxic and hypoxic situations. The brand new findings on this analysis assist researchers to grasp how hypoxia can affect utilization of metabolites in osteoblast cells, which function vital data to enhance strategies for bone regeneration.

expressionpathology
expressionpathology

GEOlimma: differential expression evaluation and have choice utilizing pre-existing microarray information

Background: Differential expression and have choice analyses are important steps for the event of correct diagnostic/prognostic classifiers of difficult human ailments utilizing transcriptomics information. These steps are significantly difficult as a result of curse of dimensionality and the presence of technical and organic noise. A promising technique for overcoming these challenges is the incorporation of pre-existing transcriptomics information within the identification of differentially expressed (DE) genes. This strategy has the potential to enhance the standard of chosen genes, improve classification efficiency, and improve organic interpretability. Whereas a lot of strategies have been developed that use pre-existing information for differential expression evaluation, present strategies don’t leverage the identities of experimental situations to create a strong metric for figuring out DE genes.

Outcomes: On this examine, we suggest a novel differential expression and have choice method-GEOlimma-which combines pre-existing microarray information from the Gene Expression Omnibus (GEO) with the widely-applied Limma methodology for differential expression evaluation.

We first quantify differential gene expression throughout 2481 pairwise comparisons from 602 curated GEO Datasets, and we convert differential expression frequencies to DE prior chances. Genes with excessive DE prior chances present enrichment in cell development and dying, sign transduction, and cancer-related organic pathways, whereas genes with low prior chances have been enriched in sensory system pathways.

We then utilized GEOlimma to 4 differential expression comparisons inside two human illness datasets and carried out differential expression, function choice, and supervised classification analyses. Our outcomes counsel that use of GEOlimma offers higher experimental energy to detect DE genes in comparison with Limma, resulting from its elevated efficient pattern dimension. Moreover, in a supervised classification evaluation utilizing GEOlimma as a function choice methodology, we noticed related or higher classification efficiency than Limma given small, noisy subsets of an bronchial asthma dataset.

Conclusions: Our outcomes exhibit that GEOlimma is a simpler methodology for differential gene expression and have choice analyses in comparison with the usual Limma methodology. Because of its concentrate on gene-level differential expression, GEOlimma additionally has the potential to be utilized to different high-throughput organic datasets.

Recombinant Human LEC (CCL16) Protein
PROTO15467-1 20ug
EUR 380.4
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.

LEC Chemokine(LEC66) Antibody
BNCA0066-250 250uL
EUR 459.6
Description: Primary antibody against LEC Chemokine(LEC66), APC conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNCA0067-250 250uL
EUR 459.6
Description: Primary antibody against LEC Chemokine(LEC67), APC conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC800066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF680 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC800066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF680 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC800067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF680 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC800067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF680 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC810066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF680R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC810066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF680R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC810067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF680R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC810067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF680R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC940066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF594 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC940066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF594 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC940067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF594 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC940067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF594 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC880066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF488A conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC880066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF488A conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC880067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF488A conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC880067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF488A conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC430066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF543 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC430066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF543 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC430067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF543 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC430067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF543 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC400066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF640R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC400066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF640R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC400067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF640R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC400067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF640R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC050066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF405M conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC050066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF405M conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC050067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF405M conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC050067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF405M conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNCAP0066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNCAP0066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNCAP0067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNCAP0067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNCB0066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), Biotin conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNCB0066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), Biotin conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNCB0067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), Biotin conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNCB0067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), Biotin conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNCR0066-250 250uL
EUR 459.6
Description: Primary antibody against LEC Chemokine(LEC66), RPE conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNCR0067-250 250uL
EUR 459.6
Description: Primary antibody against LEC Chemokine(LEC67), RPE conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNUB0066-100 100uL
EUR 250.8
Description: Primary antibody against LEC Chemokine(LEC66), Concentration: 0.2mg/mL

LEC Chemokine(LEC66) Antibody
BNUB0066-500 500uL
EUR 549.6
Description: Primary antibody against LEC Chemokine(LEC66), Concentration: 0.2mg/mL

LEC Chemokine(LEC67) Antibody
BNUB0067-100 100uL
EUR 250.8
Description: Primary antibody against LEC Chemokine(LEC67), Concentration: 0.2mg/mL

LEC Chemokine(LEC67) Antibody
BNUB0067-500 500uL
EUR 549.6
Description: Primary antibody against LEC Chemokine(LEC67), Concentration: 0.2mg/mL

LEC Chemokine(LEC66) Antibody
BNCP0066-250 250uL
EUR 459.6
Description: Primary antibody against LEC Chemokine(LEC66), PerCP conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNCP0067-250 250uL
EUR 459.6
Description: Primary antibody against LEC Chemokine(LEC67), PerCP conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNUM0066-50 50uL
EUR 474
Description: Primary antibody against LEC Chemokine(LEC66), 1mg/mL

LEC Chemokine(LEC67) Antibody
BNUM0067-50 50uL
EUR 474
Description: Primary antibody against LEC Chemokine(LEC67), 1mg/mL

LEC Chemokine(LEC66) Antibody
BNCH0066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNCH0066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNCH0067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNCH0067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC040066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF405S conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC040066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF405S conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC040067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF405S conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC040067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF405S conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC550066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF555 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC550066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF555 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC550067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF555 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC550067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF555 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC610066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF660R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC610066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF660R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC610067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF660R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC610067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF660R conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC680066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF568 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC680066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF568 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC680067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF568 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC680067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF568 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC470066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF647 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC470066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF647 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC470067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF647 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC470067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF647 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC700066-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC66), CF770 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC66) Antibody
BNC700066-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC66), CF770 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC700067-100 100uL
EUR 238.8
Description: Primary antibody against LEC Chemokine(LEC67), CF770 conjugate, Concentration: 0.1mg/mL

LEC Chemokine(LEC67) Antibody
BNC700067-500 500uL
EUR 652.8
Description: Primary antibody against LEC Chemokine(LEC67), CF770 conjugate, Concentration: 0.1mg/mL

LEC protein
30R-AL013 20 ug
EUR 327.6
Description: Purified recombinant Human LEC protein

Recombinant Human LEC/NCC-4 (CCL16)
7-01792 5µg Ask for price

Recombinant Human LEC/NCC-4 (CCL16)
7-01793 20µg Ask for price

Recombinant Human LEC/NCC-4 (CCL16)
7-01794 1mg Ask for price

Recombinant Human LEC/NCC-4 (CCL16)
HECCP-1601 5ug Ask for price

HCC-4, LEC, NCC-4, CCL16, human
RC315-27 5ug
EUR 125.26

CCL16 LEC/NCC-4 Human Recombinant Protein
PROTO15467 Regular: 20ug
EUR 380.4
Description: CCL16 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 97 amino acids and having a molecular mass of 11.2 kDa. ;The CCL16 is purified by proprietary chromatographic techniques.

LEC Recombinant Protein
40-396-0005mg 0.005 mg
EUR 311.1
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.

LEC Recombinant Protein
40-396-002mg 0.02 mg
EUR 437.1
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.

LEC Antibody / HCC-4 / CCL16
RQ4655 100ug
EUR 356.15
Description: Chemokine (C-C motif) ligand 16 (CCL16) is a small cytokine belonging to the CC chemokine family that is known under several pseudonyms, including Liver-expressed chemokine (LEC) and Monotactin-1 (MTN-1). This gene is one of several cytokine genes clustered on the q-arm of chromosome 17. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for lymphocytes and monocytes but not for neutrophils. This cytokine also shows a potent myelosuppressive activity and suppresses proliferation of myeloid progenitor cells. The expression of this gene is upregulated by IL-10.

Anti-LEC/CCL16/HCC4 antibody
STJ16100997 100 µg
EUR 424.8

Refrigerator LEC 130ltr LR111
REF1990 EACH
EUR 451.44